Neuvasq Biotechnologie is pleased to announce the appointment of Ralph Laufer, Ph.D., as its Chief…
Stephanie9 April 2024
Neuvasq Biotechnologies is a privately held research company focusing on the discovery and development of pioneering therapies to safeguard or rebuild central nervous system (CNS) barriers and improve neurovascular function for patients with severe neurological conditions.
More about our science
Advancing therapies to safeguard
or rebuild CNS barriers
and restore neurovascular function
Neuvasq Biotechnologies is a privately held research company focusing on the discovery and development of pioneering therapies to safeguard or rebuild central nervous system (CNS) barriers and improve neurovascular function for patients with severe neurological conditions.
More about our science
Join us in our mission to develop innovative therapies that truly impact patients’ lives
Latest insights and highlights
Neuvasq Biotechnologie is pleased to announce the appointment of Ralph Laufer, Ph.D., as its Chief…
Stephanie9 April 2024
Neuvasq Biotechnologies appoints World-Leading Experts to newly formed Scientific Advisory Board dedicated to its CNS…
Javier20 October 2023
Cookie policy